William Gibson: Molecular glues that finally ‘drug’ TP53
Michael Gibson, Executive Board Member at William Gibson, Medical Oncologist at Dana-Farber Cancer Institute, on X, adding:
“So proud of my son Will whose work (highlighted in this thread) is dedicated to drugging P53 which is involved in many cancers in many people.”
Quoting William Gibson‘s post:
“But I think we do see a way forward. In the fullness of time we might expect highly potent, cooperative, gain-of-function molecular glues that finally ‘drug’ TP53 and drive important biologic responses in the millions of patients that desperately need new options.
We’ll be working to expand this work to pan-p53 targeting compounds, and to make these early prototypes into more effective, glue-like compounds.
Many thanks to my enormously supportive recent/former* mentors, Stuart Schreiber and Matthew Meyerson.
And it’s been an absolute pleasure working with the extraordinarily talented incoming Harvard PhD student Ananthan Sadagopan. He is a force of nature, and key to the success of this work.
Footnotes: – The 500 million living people figure comes from Scott Lowe’s ‘Putting p53 in context’ Cell review in 2017. – I also think other molecular glues involving p53 will be possible! The natural world already made one by accident as Dan Nomura showed with asukamycin.”
Source: Michael Gibson/X and William Gibson/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023